GO:0004623 A2-type glycerophospholipase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004623 (A2-type glycerophospholipase activity) is a molecular function that removes the fatty acid at the sn-2 position of glycerophospholipids, producing free fatty acids and lysophospholipids.
• This activity is carried out by phospholipase A2 (PLA2) enzymes, including secreted sPLA2-IIA and cytosolic isoforms, which are widely expressed in inflammatory and neural cells.
• sPLA2-IIA can activate integrins in an allosteric manner, linking A2-type glycerophospholipase activity to cell adhesion and signaling.
• Inhibition of A2-type glycerophospholipase activity, for example by targeting Lcn2, modulates astrocyte phenotype and is being explored for ischemic stroke therapy.
• Cottonseed oil and other anti-inflammatory interventions reduce microglial and astrocytic activation, partly through effects on lipid mediator pathways that depend on A2-type glycerophospholipase activity.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models are essential to dissect the causal roles of PLA2 enzymes in disease [1,5].
Description
A2-type glycerophospholipase activity (GO:0004623) is a fundamental enzymatic function that cleaves the fatty acid attached to the sn-2 position of glycerophospholipids, generating a free fatty acid and a lysophospholipid. This activity is central to the production of lipid mediators such as arachidonic acid and lysophosphatidylcholine, which are involved in inflammation, membrane remodeling, and cell signaling. Researchers study this term because dysregulated A2-type glycerophospholipase activity contributes to pathologies including ischemic stroke, sepsis-associated encephalopathy, and Alzheimer's disease [1,3,4]. The enzyme family includes secreted phospholipase A2 type IIA (sPLA2-IIA), which can activate integrins allosterically, thereby influencing cell adhesion and migration. Understanding the molecular players and regulatory mechanisms of GO:0004623 is therefore critical for developing targeted therapies.
A2-type glycerophospholipase activity At A Glance
| GO ID | GO:0004623 |
|---|---|
| GO term | A2-type glycerophospholipase activity |
| Ontology | molecular_function |
| Synonym | phospholipase A2 activity; lecithinase A activity; phosphatidylcholine 2-acylhydrolase activity; secreted phospholipase A2 activity |
| Major function | Cleaves the sn-2 fatty acid from glycerophospholipids, producing free fatty acids and lysophospholipids |
| Substrates | Phosphatidylcholine, phosphatidylethanolamine, choline plasmalogen, phosphatides |
| Cofactors | Calcium is commonly required for secreted PLA2 enzymes |
| Cellular location | Secreted, cytosolic, and membrane-associated forms exist |
| Related diseases | Ischemic stroke, sepsis-associated encephalopathy, Alzheimer's disease [1,3,4] |
What Is GO:0004623?
A2-type glycerophospholipase activity (GO:0004623) is defined as a glycerophospholipase activity that hydrolyzes the ester bond at the sn-2 position of the glycerol backbone of a glycerophospholipid, releasing a free fatty acid and a lysophospholipid. Substrates include phosphatidylcholine, phosphatidylethanolamine, choline plasmalogen, and other phosphatides. This activity is synonymous with phospholipase A2 activity, lecithinase A activity, and phosphatidylcholine 2-acylhydrolase activity.
Why Is A2-type glycerophospholipase activity Important in Cell Biology?
A2-type glycerophospholipase activity is a key node in lipid signaling and inflammation. It controls the release of arachidonic acid, a precursor to prostaglandins and leukotrienes, and lysophospholipids that can act as signaling molecules. Dysregulation of this activity is implicated in acute brain injury, neurodegenerative diseases, and systemic inflammatory conditions [1,3,4]. Moreover, sPLA2-IIA can directly activate integrins, linking this enzymatic activity to cell adhesion and migration. Therefore, understanding GO:0004623 is essential for therapeutic development targeting inflammatory and neurological disorders.
• Produces lipid mediators that drive inflammation and resolve it.
• Modulates membrane composition and fluidity.
• Influences astrocyte and microglial activation in stroke and neuroinflammation [1,3].
• Contributes to sepsis-associated encephalopathy via oxidative stress and NF-κB signaling.
• Links to Alzheimer's disease through NLRP3 inflammasome activation.
• sPLA2-IIA activates integrins, affecting cell adhesion and migration.
• Potential target for anti-inflammatory therapies in ischemic stroke.
• Involved in gut microbiota-brain axis modulation.
• Can be regulated by dietary components such as cottonseed oil.
• Provides a mechanistic basis for CRISPR-based functional studies [1,5].
Core Mechanisms of A2-type glycerophospholipase activity
Substrate Binding and sn-2 Hydrolysis
In simple terms: The enzyme grabs a phospholipid and cuts off the fatty acid at the middle position.
A2-type glycerophospholipase enzymes bind glycerophospholipids such as phosphatidylcholine and phosphatidylethanolamine and hydrolyze the ester bond at the sn-2 position, releasing a free fatty acid and a lysophospholipid. This reaction is calcium-dependent for many secreted PLA2s.
Calcium-Dependent Activation
In simple terms: Calcium acts like a switch that turns on the enzyme.
Secreted phospholipase A2 type IIA (sPLA2-IIA) requires calcium for catalytic activity and can undergo allosteric activation upon binding to integrins, which modulates its function in cell adhesion and signaling.
Allosteric Regulation by Integrins
In simple terms: Integrins can change the enzyme's shape to make it more active.
sPLA2-IIA activates integrins in an allosteric manner, and this interaction can reciprocally influence the enzyme's activity, linking A2-type glycerophospholipase activity to cell-matrix adhesion and migration.
Inflammatory Signaling and Lipid Mediator Production
In simple terms: The products of this enzyme fuel inflammation signals.
The free fatty acids and lysophospholipids generated by A2-type glycerophospholipase activity serve as precursors for eicosanoids and other inflammatory mediators. Inhibition of this activity, for example by targeting Lcn2, can modulate astrocyte phenotype and reduce neuroinflammation in ischemic stroke models.
Modulation by Dietary and Pharmacological Agents
In simple terms: Certain diets and drugs can dial down this enzyme's activity.
Cottonseed oil alleviates ischemic stroke injury by inhibiting inflammatory activation of microglia and astrocytes, partly through effects on lipid signaling pathways that involve A2-type glycerophospholipase activity. Similarly, Huanglian Jiedu Decoction improves cognitive function in APP/PS1 mice by inhibiting NLRP3 inflammasome activation mediated by gut microbiota, which may intersect with phospholipase A2 pathways.
Key Genes Involved in GO:0004623 A2-type glycerophospholipase activity
The following genes and proteins are directly or indirectly associated with A2-type glycerophospholipase activity (GO:0004623) based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PLA2G2A | Encodes sPLA2-IIA, a secreted phospholipase A2 that hydrolyzes sn-2 fatty acids and activates integrins | Target for anti-inflammatory and anti-metastatic studies |
| Lcn2 | Lipocalin-2, modulates astrocyte phenotype and inflammation; inhibition reduces ischemic stroke injury | Potential therapeutic target in stroke |
| P2X7R | P2X7 receptor, induces A2-type astrocyte activation and upstream inflammatory markers | Model for neuroinflammation studies |
| NLRP3 | Inflammasome component; its activation is linked to cognitive decline and is modulated by gut microbiota | Target in Alzheimer's disease models |
| GFAP | Astrocyte marker; A2-type astrocytes are neuroprotective and express GFAP | Used to classify astrocyte phenotypes |
| ERK | Kinase in MAPK pathway; involved in oxidative stress and NF-κB signaling in microglia and astrocytes | Readout for inflammatory pathway activation |
| NF-κB | Transcription factor driving pro-inflammatory gene expression; inhibited by Orexin-A in sepsis-associated encephalopathy | Central node in neuroinflammation |
| sPLA2-IIA | Secreted phospholipase A2 type IIA; activates integrins allosterically | Therapeutic target in inflammation and cancer |
| COX-2 | Cyclooxygenase-2, downstream of arachidonic acid released by PLA2 | Inflammatory mediator production |
| 5-LOX | Lipoxygenase, converts arachidonic acid to leukotrienes | Inflammatory pathway enzyme |
| cPLA2 | Cytosolic phospholipase A2, another A2-type glycerophospholipase | Involved in eicosanoid production |
| iPLA2 | Calcium-independent phospholipase A2, maintains membrane homeostasis | Role in phospholipid remodeling |
| LPCAT | Lysophosphatidylcholine acyltransferase, reacylates lysophospholipids | Counteracts PLA2 activity |
| PPARγ | Nuclear receptor activated by fatty acid derivatives | Links lipid signaling to gene expression |
| TLR4 | Toll-like receptor 4, upstream of inflammatory activation in microglia | Innate immune sensing |
| IL-1β | Pro-inflammatory cytokine processed by NLRP3 inflammasome | Biomarker of neuroinflammation |
| TNF-α | Pro-inflammatory cytokine induced in sepsis-associated encephalopathy | Therapeutic target |
| BDNF | Neurotrophic factor; cognitive function improved by Huanglian Jiedu Decoction | Marker of synaptic plasticity |
How Is A2-type glycerophospholipase activity Regulated?
A2-type glycerophospholipase activity is regulated at multiple levels. Secreted PLA2 enzymes require calcium for catalysis and can be allosterically activated by integrin binding. Inflammatory stimuli such as P2X7 receptor activation induce A2-type astrocyte activation and upregulate upstream inflammatory markers. Conversely, anti-inflammatory interventions, including Orexin-A, inhibit the ERK/NF-κB signaling pathway in microglia and astrocytes, potentially reducing PLA2 activity. Dietary components like cottonseed oil can suppress microglial and astrocytic inflammatory activation, indirectly modulating lipid mediator production. Additionally, gut microbiota-derived metabolites influence NLRP3 inflammasome activation, which may intersect with phospholipase A2 pathways in Alzheimer's disease models.
A2-type glycerophospholipase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| Lcn2 | Ischemic stroke; astrocyte phenotype modulation | Knockout mouse or astrocyte-specific overexpression |
| PLA2G2A | Inflammation and cancer; integrin activation | Point mutation to disrupt catalytic activity |
| NLRP3 | Alzheimer's disease; inflammasome activation | Knock-in of disease-associated variants |
| P2X7R | Neuroinflammation; A2-type astrocyte activation | Knockout or pharmacological inhibition |
| ERK | Sepsis-associated encephalopathy; oxidative stress | Overexpression of constitutively active ERK |
Ischemic Stroke
A2-type glycerophospholipase activity contributes to neuroinflammation after ischemic stroke. Inhibition of Lcn2, which modulates astrocyte phenotype, reduces ischemic stroke injury in preclinical models. Cottonseed oil alleviates ischemic stroke injury by inhibiting inflammatory activation of microglia and astrocytes, partly through effects on lipid signaling.
Sepsis-Associated Encephalopathy
Orexin-A attenuates the inflammatory response in sepsis-associated encephalopathy by modulating oxidative stress and inhibiting the ERK/NF-κB signaling pathway in microglia and astrocytes. This suggests that A2-type glycerophospholipase activity, which feeds into these pathways, may be a therapeutic target.
Alzheimer's Disease
Huanglian Jiedu Decoction improves cognitive function in APP/PS1 mice by inhibiting NLRP3 inflammasome activation mediated by gut microbiota. Since PLA2 activity can influence inflammasome activation, targeting A2-type glycerophospholipase activity may have therapeutic potential in Alzheimer's disease.
Cancer and Inflammation
sPLA2-IIA activates integrins in an allosteric manner, promoting cell adhesion and migration, which are hallmarks of cancer progression. Thus, A2-type glycerophospholipase activity is implicated in tumorigenesis and inflammatory diseases.
From A2-type glycerophospholipase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PLA2G2A reduce inflammation? | Knockout cell line or mouse |
| Does a specific point mutation abolish catalytic activity? | Point mutation knock-in |
| Can a tagged version track subcellular localization? | Knock-in of fluorescent tag |
| Does overexpression of Lcn2 worsen stroke outcome? | Overexpression cell model |
| Which genes interact with A2-type glycerophospholipase activity? | CRISPR library screening [1,5] |
| How does gut microbiota modulate NLRP3 via PLA2? | Knock-in of humanized NLRP3 |
How to Study the A2-type glycerophospholipase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Lipidomics (LC-MS) | Free fatty acids and lysophospholipids | Quantify PLA2 activity in cells |
| CRISPR knockout screen | Genes affecting PLA2 activity [1,5] | Identify regulators |
| PLA2 activity assay | Enzymatic hydrolysis of sn-2 fatty acid | Measure catalytic activity |
| Immunofluorescence | Protein localization and astrocyte markers | Assess A2-type astrocyte activation |
| Western blot | Protein expression of PLA2 isoforms | Validate knockout or overexpression |
| qRT-PCR | mRNA levels of PLA2 genes | Measure transcriptional regulation |
| Flow cytometry | Integrin activation on cell surface | Study allosteric activation |
| ELISA | Cytokine levels (IL-1β, TNF-α) [4,7] | Assess inflammatory response [4,7] |
Lipidomics and Mass Spectrometry
Mass spectrometry-based lipidomics can quantify the products of A2-type glycerophospholipase activity, such as free fatty acids and lysophospholipids, in cells and tissues.
CRISPR-Cas9 Knockout Screening
Genome-wide CRISPR knockout screens can identify genes that regulate A2-type glycerophospholipase activity or its downstream inflammatory effects [1,5].
Phospholipase A2 Activity Assays
Enzymatic assays using fluorescent or radioactive substrates measure the catalytic activity of PLA2 enzymes in vitro and in cell lysates.
Immunofluorescence and Imaging
Immunofluorescence can visualize the localization of PLA2 enzymes and their substrates in cells, and assess astrocyte reactivity markers like GFAP.
How CRISPR Can Be Used to Study GO:0004623 A2-type glycerophospholipase activity
Knockout
CRISPR knockout of PLA2G2A or Lcn2 can abolish A2-type glycerophospholipase activity, allowing researchers to study its role in inflammation and stroke [1,5].
Point Mutation
Introducing point mutations in the catalytic site of PLA2 enzymes can distinguish enzymatic activity from non-enzymatic functions, such as integrin binding.
Knock-in
Knock-in of fluorescent tags or disease-associated variants enables tracking of PLA2 localization and function in live cells.
Overexpression
Overexpression of sPLA2-IIA or Lcn2 can model gain-of-function effects in inflammatory diseases and cancer [1,5].
How EDITGENE Supports A2-type glycerophospholipase activity Research
Researchers studying A2-type glycerophospholipase activity-related genes often need to determine whether a candidate gene is causally involved in lipid signaling, inflammation, or disease progression. EDITGENE provides comprehensive CRISPR-based services to accelerate this discovery.
Contact EDITGENE today to design your custom CRISPR model for A2-type glycerophospholipase activity research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PRDX6 Knockout SRA01/04 Cell Line | EDJ-KQ67 | Human | 9588 | Details Get a Quote |
| Prdx6 Knockout TM4 Cell Line | EDJ-KQ76 | Mouse | 11758 | Details Get a Quote |
| PLA2G4A Knockout HEK293 Cell Line | EDJ-KQ726 | Human | 5321 | Details Get a Quote |
| PLA2G4C Knockout HEK293 Cell Line | EDJ-KQ727 | Human | 8605 | Details Get a Quote |
| PLA2G4E Knockout HEK293 Cell Line | EDJ-KQ728 | Human | 123745 | Details Get a Quote |
| PLA2G4F Knockout HEK293 Cell Line | EDJ-KQ729 | Human | 255189 | Details Get a Quote |
| PRDX6 Knockout HEK293 Cell Line | EDJ-KQ1098 | Human | 9588 | Details Get a Quote |
| PLA2G2D Knockout HEK293 Cell Line | EDJ-KQ1257 | Human | 26279 | Details Get a Quote |
| PLA2G2E Knockout HEK293 Cell Line | EDJ-KQ1258 | Human | 30814 | Details Get a Quote |
| PLA2G3 Knockout HEK293 Cell Line | EDJ-KQ1259 | Human | 50487 | Details Get a Quote |
| PLA2G2F Knockout HEK293 Cell Line | EDJ-KQ1260 | Human | 64600 | Details Get a Quote |
| PLA2G12A Knockout HEK293 Cell Line | EDJ-KQ1261 | Human | 81579 | Details Get a Quote |
| PLA2G12B Knockout HEK293 Cell Line | EDJ-KQ1262 | Human | 84647 | Details Get a Quote |
| PLA2G1B Knockout HEK293 Cell Line | EDJ-KQ1263 | Human | 5319 | Details Get a Quote |
| PLA2G5 Knockout HEK293 Cell Line | EDJ-KQ1264 | Human | 5322 | Details Get a Quote |
Displaying Records 1 To 15 Of 149 Records
- 1
- 2
- Next Page »
Frequently Asked Questions About A2-type glycerophospholipase activity
What is A2-type glycerophospholipase activity?
It is a molecular function (GO:0004623) that cleaves the fatty acid at the sn-2 position of glycerophospholipids, producing free fatty acids and lysophospholipids.
What genes are involved in A2-type glycerophospholipase activity?
Key genes include PLA2G2A (sPLA2-IIA), Lcn2, and other phospholipase A2 family members [1,5].
What diseases are associated with A2-type glycerophospholipase activity?
Ischemic stroke, sepsis-associated encephalopathy, Alzheimer's disease, and cancer [1,3,4,5].
How is A2-type glycerophospholipase activity regulated?
It is regulated by calcium, integrin binding, inflammatory stimuli, and dietary factors [3,5,7].
What are the substrates of A2-type glycerophospholipase activity?
Phosphatidylcholine, phosphatidylethanolamine, choline plasmalogen, and other phosphatides.
What is the role of sPLA2-IIA in this activity?
sPLA2-IIA is a secreted phospholipase A2 that hydrolyzes sn-2 fatty acids and can activate integrins allosterically.
How can CRISPR be used to study A2-type glycerophospholipase activity?
CRISPR knockout, point mutation, knock-in, and overexpression models allow functional dissection of PLA2 genes [1,5].
What methods measure A2-type glycerophospholipase activity?
Lipidomics, enzymatic assays, and immunofluorescence are commonly used [1,5,8].
Is A2-type glycerophospholipase activity involved in neuroinflammation?
Yes, it contributes to astrocyte and microglial activation in stroke and sepsis-associated encephalopathy [1,7].
What is the GO ID for A2-type glycerophospholipase activity?
GO:0004623.
Conclusion
A2-type glycerophospholipase activity (GO:0004623) is a central enzymatic function in lipid signaling and inflammation, with far-reaching implications for ischemic stroke, sepsis-associated encephalopathy, Alzheimer's disease, and cancer [1,3,4,5]. Understanding its regulation and downstream effects requires robust experimental models, and CRISPR-based approaches are indispensable for causal gene discovery [1,5]. EDITGENE offers a full suite of services to support researchers in this field.
References
- 1. Xiao R et al.. 2025. Regulating astrocyte phenotype by Lcn2 inhibition toward ischemic stroke therapy.. Biomaterials 317:123102 PMID: 39836995
- 3. Liu M et al.. 2020. Cottonseed oil alleviates ischemic stroke injury by inhibiting the inflammatory activation of microglia and astrocyte.. J Neuroinflammation 17(1):270 PMID: 32917229
- 4. Zhang Y et al.. 2025. Huanglian Jiedu Decoction improves the"central-peripheral"inflammatory microenvironment and enhances the cognitive function of APP/PS1 mice by inhibiting the activation of NLRP3 inflammasome mediated by gut microbiota.. Chin Med 20(1):123 PMID: 40770806
- 5. Takada Y et al.. 2017. Secreted Phospholipase A2 Type IIA (sPLA2-IIA) Activates Integrins in an Allosteric Manner.. Adv Exp Med Biol 925:103-115 PMID: 27864802
- 7. Guo J et al.. 2024. Orexin-A Attenuates the Inflammatory Response in Sepsis-Associated Encephalopathy by Modulating Oxidative Stress and Inhibiting the ERK/NF-κB Signaling Pathway in Microglia and Astrocytes.. CNS Neurosci Ther 30(11):e70096 PMID: 39508266
- 8. Campagno KE et al.. 2024. Increased Pan-Type, A1-Type, and A2-Type Astrocyte Activation and Upstream Inflammatory Markers Are Induced by the P2X7 Receptor.. Int J Mol Sci 25(16) PMID: 39201471
